ArticleParkinson's disease2026
Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson's Disease: A Randomized, Double-Blind Clinical Trial.
Article in Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mesenchymal Stem Cells and Extracellular Vesicles for Neurodegenerative Diseases: Therapeutic Advances and Challenges.International journal of nanomedicine · 2026Review
- Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson's Disease: A Randomized, Double-Blind Clinical Trial.Parkinson's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The purpose of this trial was to evaluate preliminary efficacy and safety of multiple intravenous infusions of autologous, Hope Biosciences adipose-derived mesenchymal stem cells (HB-adMSCs) for the treatment of patients with Parkinson's disease (PD). Methods: A total of Results: HB-adMSC treatment was well tolerated and safe, with only one SAE reported, which was deemed unrelated to the investigational product. In total, 81 AEs were recorded, 79 of which were mild, one moderate, and one severe. Neurological disorders were the most commonly reported AEs, with a higher incidence in the placebo group (66.7%) compared with the HB-adMSC group (46.7%). No deaths occurred, and no clinically meaningful changes were observed in laboratory parameters from baseline to the EOS for either group. Efficacy analyses revealed no clear treatment effect in MDS-UPDRS II scores between the HB-adMSC and Placebo groups. Conclusion: Multiple intravenous infusions of autologous HB-adMSCs were found to be safe and feasible in the patients with PD. Efficacy outcomes should be interpreted with caution, as this small, early-phase study was not designed or powered to demonstrate definitive efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.